Ophthalmic Gel with Cyclodextrin Complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic treatments for post-operative inflammation and infection following eye surgeries often require separate administration of multiple medications, which can be cumbersome for elderly patients with impaired vision, and suffer from compliance issues due to complex application schedules and reciprocal displacement of active ingredients from the tear film.
Innovation Solution
A combination ophthalmic composition comprising a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), and an antibiotic, formulated as a gel or liquid drop, which includes complexing agents like cyclodextrin to stabilize the active ingredients and viscosifying agents like methylcellulose to maintain stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple active ingredients are administered separately as eye drops, then each ingredient can be delivered to the ocular surface, but patient compliance deteriorates and reciprocal displacement occurs
Solution Approach 1:
The patent combines multiple active ingredients (corticosteroid, NSAID, and antibiotic) into a single ophthalmic composition that can be administered as one formulation. This merging approach maintains the therapeutic benefits of each ingredient while eliminating the compliance issues associated with administering multiple separate eye drops, directly resolving the technical contradiction between reliability and ease of operation.
2Adaptability or versatility
If multiple active ingredients are administered separately, then comprehensive treatment is achieved, but application complexity and time increase
Solution Approach 1:
By merging multiple active ingredients into a single ophthalmic composition, the patent reduces the number of application steps from multiple separate administrations to a single administration. This maintains comprehensive treatment coverage while significantly reducing the time and complexity lost in the application process.
3Ease of operation
If active ingredients are applied in the tear film, then ocular surface delivery is achieved, but contact time and absorption become difficult to control
Solution Approach 1:
The patent modifies the physical parameters of the ophthalmic composition by incorporating viscosity-modifying agents and complexing agents. These parameter changes increase the residence time and stability of the active ingredients on the ocular surface, providing better control over contact time and absorption while maintaining ease of administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination product enhances compliance, reduces side effects, and provides improved therapeutic efficacy by maintaining effective concentrations of active ingredients on the ocular surface, thereby effectively treating or preventing ocular inflammation and infection with reduced complexity in administration.
Implementation Method 1
which includes complexing agents like cyclodextrin to stabilize the active ingredients
Implementation Method 2
and viscosifying agents like methylcellulose to maintain stability and efficacy
Data Source
AI summary
Compositions comprising at least two of a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), and an antibiotic find use in treating or preventing eye conditions in subjects in need thereof. Methods of treatment or prevention of eye conditions comprise administering an effective amount of the disclosed compositions to the affected eye(s). Methods of preparing a composition comprising an NSAID and antibiotic comprise separately complexing the NSAID and antibiotic with cyclodextrin.